Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
130,702,820
-
Total 13F shares
-
37,693,097
-
Share change
-
+2,484,027
-
Total reported value
-
$600,638,157
-
Put/Call ratio
-
55%
-
Price per share
-
$15.95
-
Number of holders
-
185
-
Value change
-
+$41,433,093
-
Number of buys
-
90
-
Number of sells
-
71
Institutional Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2025
As of 31 Dec 2025,
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) was held by
185 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,693,097 shares.
The largest 10 holders included
BlackRock, Inc., ARROWSTREET CAPITAL, LIMITED PARTNERSHIP, STATE STREET CORP, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, JACOBS LEVY EQUITY MANAGEMENT, INC, and GOLDMAN SACHS GROUP INC.
This page lists
185
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.